News & Publications
Publications
Link JM, Rich, CM, Korat M, Burrows, GG, Offner H, Vanderbark AA
Monomeric DR2/MOG035-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice
Clin Immunol. (2007), doi:10.1016/j.clim.2006.12.002 Pubmed Reference
Wang C, Gold BG, Kaler LJ, Yu X, Afentoulis ME, Burrows GG, Vandenbark AA, Bourdette DN, Offner H.
Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.
J Neurochem. 2006 Sep;98(6):1817-27. Epub 2006 Aug 3. Pubmed Reference
Adamus G, Burrows GG, Vandenbark AA, Offner H.
Treatment of autoimmune anterior uveitis with recombinant TCR ligands.
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2555-61. Pubmed Reference
Offner H, Subramanian S, Wang C, Afentoulis M, Vandenbark AA, Huan J, Burrows GG.
Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury.
J Immunol. 2005 Sep 15;175(6):4103-11. Pubmed Reference
Burrows GG.
Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.
Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):185-93. Review. Pubmed Reference
Finn TP, Jones RE, Rich C, Dahan R, Link J, David CS, Chou YK, Offner H, Vandenbark AA.
HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes.
J Neurosci Res. 2004 Oct 1;78(1):100-14. Pubmed Reference
Chou YK, Culbertson N, Rich C, LaTocha D, Buenafe AC, Huan J, Link J, Wands JM, Born WK, Offner H, Bourdette DN, Burrows GG, Vandenbark AA.
T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice.
J Neurosci Res. 2004 Sep 1;77(5):670-80. Pubmed Reference
Rich C, Link JM, Zamora A, Jacobsen H, Meza-Romero R, Offner H, Jones R, Burrows GG, Fugger L, Vandenbark AA.
Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice.
Eur J Immunol. 2004 May;34(5):1251-61. Pubmed Reference
Huan J, Subramanian S, Jones R, Rich C, Link J, Mooney J, Bourdette DN, Vandenbark AA, Burrows GG, Offner H.
Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch.
J Immunol. 2004 Apr 1;172(7):4556-66. Pubmed Reference
Wang C, Mooney JL, Meza-Romero R, Chou YK, Huan J, Vandenbark AA, Offner H, Burrows GG.
Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation.
J Immunol. 2003 Aug 15;171(4):1934-40. Pubmed Reference
Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, Fugger L, Offner H, Jones R, Burrows GG.
Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice.
J Immunol. 2003 Jul 1;171(1):127-33. Pubmed Reference
Burrows GG, Chou YK, Wang C, Chang JW, Finn TP, Culbertson NE, Kim J, Bourdette DN, Lewinsohn DA, Lewinsohn DM, Ikeda M, Yoshioka T, Allen CN, Offner H, Vandenbark AA.
Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells.
J Immunol. 2001 Oct 15;167(8):4386-95. Pubmed Reference
Chang JW, Mechling DE, Bachinger HP, Burrows GG.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
J Biol Chem. 2001 Jun 29;276(26):24170-6. Epub 2001 Apr 23. Pubmed Reference
Burrows GG, Adlard KL, Bebo BF Jr, Chang JW, Tenditnyy K, Vandenbark AA, Offner H.
Regulation of encephalitogenic T cells with recombinant TCR ligands.
J Immunol. 2000 Jun 15;164(12):6366-71. Pubmed Reference
Burrows GG, Chang JW, Bachinger HP, Bourdette DN, Offner H, Vandenbark AA.
Design, engineering and production of functional single-chain T cell receptor ligands.
Protein Eng. 1999 Sep;12(9):771-8. Pubmed Reference
Burrows GG, Bebo BF Jr, Adlard KL, Vandenbark AA, Offner H.
Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis.
J Immunol. 1998 Dec 1;161(11):5987-96. Pubmed Reference
